MCL1 and acute myeloid leukemia: However, venetoclax monotherapy is less effective in AML [22,23], as many AML cells also express high levels of another pro-survival protein, induced myeloid leukemia cell differentiation protein (MCL-1), which venetoclax does not target [24,25,26].